An observational study in Lymphoedema, sponsored by The Greater Poland Cancer Centre. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.
Sponsored by The Greater Poland Cancer Centre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Lymphoedema, a chronic condition caused by the accumulation of protein-rich fluid in the intercellular spaces due to impaired lymphatic function, is a common complication in cancer patients. It can lead to visible swelling, discomfort, and mobility issues, but most frequently affects the limbs. This condition not only impacts patients physically but also has significant psychological consequences, including reduced quality of life, social stigma, and challenges with returning to daily activities.
Oncology patients are particularly at risk for developing lymphoedema due to factors such as lymphadenectomy, radiotherapy, and extensive surgical procedures. Up to 30% of breast cancer survivors develop lymphoedema, and it is also a common complication in patients treated for other cancers, such as those involving the cervix, vulva, prostate, and bladder. Despite the importance of early detection, diagnostic tools for assessing lymphatic dysfunction are often specialised and not suitable for routine screening in clinical practice.
The primary goal of this study is to explore the early signs of lymphatic dysfunction in cancer patients before evident clinical symptoms, with the aim of identifying individuals at risk of developing lymphoedema. This will provide valuable information that could guide early interventions and preventive measures to reduce the severity or even prevent the onset of lymphoedema. By focusing on early, subclinical dysfunction, the study seeks to contribute to improving both the clinical management of lymphatic complications and the overall quality of life for oncology patients. Regular monitoring and timely physiotherapy interventions could play a key role in enhancing recovery outcomes and reducing the long-term impact of lymphoedema.
Lymphoedema is a chronic condition characterised by an increase in body volume due to the accumulation of protein-rich fluid and cellular debris in the interstitial spaces, resulting from impaired lymphatic vessel function. It can affect various areas of the body, such as the external genitalia, abdomen, and face, but most commonly occurs in the limbs, leading to visible swelling and associated discomfort.
The main risk factors for lymphoedema include lymphadenectomy, radiotherapy, extensive surgical procedures, and obesity. Oncology patients frequently experience this condition as a complication of cancer treatment. According to data from the World Health Organization, up to 30% of breast cancer survivors develop lymphoedema. It is also a common complication in patients treated for other cancers usually as a result of surgical removal of lymph nodes or radiotherapy that damages structures of the lymphatic system (cancer of the: cervix \~ 30%; vulva \~ 27%; sarcoma \~ 27%; penis \~ 25% melanoma \~ 23%; prostate \~ 18%; bladder \~ 15%; testes: \~ 10%).
Lymphoedema diagnosis is based on clinical examination and the exclusion of other causes, primarily chronic venous insufficiency and thrombosis. Standard diagnostic methods like lymphoscintigraphy and indocyanine green (ICG) dye lymphography require specialised equipment and conditions, making them less suitable for routine screening to assess lymphatic damage and the risk of lymphoedema development.
Individuals affected by lymphoedema experience not only physical symptoms such as inflammation and mobility issues but also psychological effects, including reduced quality of life, social stigma, and challenges in returning to work. According to the International Society of Lymphology (ISL), lymphoedema treatment should be interdisciplinary, incorporating a comprehensive range of therapeutic approaches such as pharmacotherapy, surgery, multi-layer compression, pneumatic compression, manual lymphatic drainage, and specialised exercises to enhance lymph flow. As the course of treatment is prolonged and the results are not fully satisfactory, methods and programmes to prevent the formation and development of lymphoedema are of particular importance, both clinically and economically.
Regular monitoring of lymphatic system function in oncology patients and the early implementation of physiotherapy can significantly reduce the risk of lymphoedema or limit its severity, ultimately improving patients' quality of life and recovery outcomes.
Purpose of the research: The aim of the project is to assess early - subclinical peripheral lymphatic system dysfunction resulting from various treatment modalities (surgery, radiotherapy, brachytherapy) in oncology patients. The study will include patients with breast cancer, malignant urinary and genital cancers, both treated surgically and/or with brachytherapy. Recruited patients' body composition will be assessed using non-invasive technology of spectroscopic bioimpedance analysis (BIA) with a body composition analyser - SOZO® Digital Health Platform apparatus. Measurements will be taken three times: (1) before the start of treatment on admission to the hospital, (2) after the applied treatment before the patient is discharged, and (3) at the standard follow-up visit two/three months after the end of treatment in the hospital. The assessment of the efficiency of the lymphatic system provides information on the appropriateness of taking preventive measures to prevent the development of lymphoedema of the limbs.
529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.
This study's planned enrollment of 600 is above the median of 103 across 145 observational studies indexed under Lymphedema.
Browse Lymphedema studies →The Greater Poland Cancer Centre is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals affected by lymphoedema experience not only physical symptoms such as inflammation and mobility issues but also psychological effects, including reduced quality of life, social stigma, and challenges in returning to work.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* 150 women with malignant tumours of the urinary and genital systems * 150 men with malignant tumours of the urinary and genital systems * 150 patients with malignant tumours of the nipple (breast) * 150 patients with malignant tumours of the nipple (breast) and malignant tumours of the urinary and genital systems treated with brachytherapy
L-Dex ratio
The assessment of lymphoedema will be performed using non-invasive technology of spectroscopic bioimpedance analysis (BIA) with a body composition analyser - SOZO® Digital Health Platform apparatus and measured as L-Dex parameter. L-Dex ratio will be calculated by dividing the bioimpedance reading of the affected limb by the bioimpedance reading of the unaffected limb.
Time frame: Time Frame: Metrics assessed at baseline (within two weeks before treatment), after treatment (up to 2 weeks after completing treatment/intervention), and during follow-up (up to 8 weeks ± 2 weeks after completing treatment/intervention)
BMI
Body Mass Index; weight in kilograms (kg) and height in meter (m) will be combined to report BMI in kg/m\^2. The parameters will be measured using spectroscopic bioimpedance analysis (BIA) with a body composition analyser - SOZO® Digital Health Platform apparatus.
Time frame: Time Frame: Metrics assessed at baseline (within two weeks before treatment), after treatment (up to 2 weeks after completing treatment/intervention), and during follow-up (up to 8 weeks ± 2 weeks after completing treatment/intervention)
Percent body fat
Body fat mass in kilograms (kg) and weight in kilograms (kg) will be combined to report Percent body fat in kg/kg\*100 (%). The parameters will be measured using spectroscopic bioimpedance analysis (BIA) with a body composition analyser - SOZO® Digital Health Platform apparatus.
Time frame: Time Frame: Metrics assessed at baseline (within two weeks before treatment), after treatment (up to 2 weeks after completing treatment/intervention), and during follow-up (up to 8 weeks ± 2 weeks after completing treatment/intervention)
Percent body water
Total body water mass in kilograms (kg) and weight in kilograms (kg) will be combined to report Percent total body water in kg/kg\*100 (%). The parameters will be measured using spectroscopic bioimpedance analysis (BIA) with a body composition analyser - SOZO® Digital Health Platform apparatus.
Time frame: Time Frame: Metrics assessed at baseline (within two weeks before treatment), after treatment (up to 2 weeks after completing treatment/intervention), and during follow-up (up to 8 weeks ± 2 weeks after completing treatment/intervention)
Started Jan 2025 (actual). Primary completion is estimated for Dec 2029, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Greater Poland Cancer Centre